Overview

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Status:
Recruiting

Trial end date:
2025-10-21

Target enrollment:

Participant gender:

Summary

This study is a multicenter, non randomized, single arm, open clinical trial. The selected disease was relapsed / refractory NHL, and the disease was classified into highly aggressive lymphoma, invasive lymphoma and inert lymphoma; Highly invasive NHL included Burkitt lymphoma (BL), lymphoblastic lymphoma (LBL), high-grade B-cell lymphoma, etc; Invasive NHL includes diffuse large B-cell lymphoma, mantle cell lymphoma and peripheral T-cell lymphoma; Inert NHL contains follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

Phase:

N/A

Details

Lead Sponsor:

Hebei Senlang Biotechnology Inc., Ltd.

Collaborator:

Hebei Medical University Fourth Hospital

Treatments:

Cyclophosphamide
Fludarabine